---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-26-000056"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2026-08-06T20:05:37+00:00"
generated_at: "2026-08-06T20:07:41.085461+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Maravai Q2 revenue up 8.5% to $51.4M; raises FY2026 Adj EBITDA guidance to $33-35M

## Summary
- Q2 revenue $51.4M (+8.5% YoY); net loss narrowed to $(21.6)M from $(69.8)M; Adj EBITDA $8.7M vs $(10.4)M loss.
- TriLink revenue $34.7M (+11.5% YoY) driven by Discovery mRNA and GMP consumables; Cygnus $16.8M (+2.8%).
- Full year 2026 Adj EBITDA guidance raised to $33M-$35M; revenue guidance reiterated at $205M-$215M.
- Opened GMP enzyme manufacturing facility; ModTail product line has 125+ active customers including leading biopharma.

## SEC filing metadata
- accession: 0001823239-26-000056
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2026-08-06T20:05:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323926000056/0001823239-26-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323926000056/mrvi-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-26-000056
- JSON: https://secwatch.observer/filing/0001823239-26-000056.json
- Plain text: https://secwatch.observer/filing/0001823239-26-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.